Daewoong Pharmaceutical Co., Ltd.
Daewoong Pharmaceutical announced that its idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin received a recommendation to continue its global Phase 2 clinical trial.
Safety Review
The third Independent Data Monitoring Committee (IDMC) review confirmed the safety of Bersiporocin and recommended continuation of the study.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients.
- No significant safety concerns were found to impact the trial's continuation.
The study is progressing as planned, with approximately 92% of the target population enrolled.
Author's summary: Daewoong Pharmaceutical's Bersiporocin continues global Phase 2 clinical trial.
More News
- GSK acquires exclusive rights from Syndivia for antibody drug conjugate in prostate cancer
- The Global Cleanergy Shift: A Watershed Moment for Investors () | aktiencheck.de
- Smallest OLED Pixels So Far
- The Tech Odyssey: AI, Moonshots, and Musk's Encyclopedia of Everything
- Major Candy Company Files Chapter 11 Bankruptcy Amid Halloween Week Shock - CCE l ONLINE NEWS
- Dodgers’ Freddie Freeman ends 18-inning World Series Game 3 thriller
- Egyptian journalist Ismail Alexandrani held for past month - one month too many!
- Santa Cruz Warriors release 2025 training camp roster | NBA G League
- The Global Cleanergy Shift: A Watershed Moment for Investors () | aktiencheck.de
- The Coming Dementia Crisis—and the Cost of Doing Nothing